眾興菌業(002772.SZ)擬斥3000萬元設立眾安生物 進行食用菌研發及工廠化生產
格隆匯12月23日丨眾興菌業(002772.SZ)公佈,公司於2019年12月23日召開第三屆董事會第二十六次會議審議通過了《關於對外投資設立全資子公司的議案》。公司擬以自有資金3000萬元人民幣投資設立全資子公司“天水眾安生物科技有限責任公司”(暫定名,“眾安生物”)。
天水眾安生物科技有限責任公司擬定經營範圍:食用菌、藥用菌及其輔料的生產、銷售、微生物技術、生物工程技術、農業新技術的研發、應用、研究、推廣、農副土特產品的生產、加工、銷售。
此次對外投資擬設立全資子公司的目的為進行食用菌的研發及工廠化生產,進一步提升公司食用菌的研發能力及擴大食用菌種植規模,提高市場佔有率。此次擬以自有資金投資設立全資子公司,不會對公司財務及經營狀況產生不利影響,不存在損害公司及全體股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.